Anteris Technologies Global (ASX:AVR) EBIT: A$-141.52 Mil (TTM As of Mar. 2026)


ASX:AVR Anteris Technologies Global Corp ASX:AVR
50 GF Score
Price A$15.00
! 7 Warning Signs
View Full Analysis

What is Anteris Technologies Global EBIT?

Anteris Technologies Global ASX:AVR +10.05% 50 EBIT is A$-141.52 Mil as of Mar. 2026. GuruFocus rates ASX:AVR with a GF Score™ of 50/100. The stock has 7 warning signs investors should review.

Anteris Technologies Global's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was A$-31.89 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was A$-141.52 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Anteris Technologies Global's annualized ROC % for the quarter that ended in Mar. 2026 was -987.44%. Anteris Technologies Global's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -1,146.81%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Anteris Technologies Global's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -13.30%.


Anteris Technologies Global  (ASX:AVR) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Anteris Technologies Global's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-136.84 * ( 1 - 0% )/( (13.075 + 14.641)/ 2 )
=-136.84/13.858
=-987.44 %

where

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=419.979 - 16.349 - ( 402.846 - max(0, 19.514 - 408.503+402.846))
=14.641

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Anteris Technologies Global's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-127.56/( ( (10.92 + max(-27.045, 0)) + (11.326 + max(-11.989, 0)) )/ 2 )
=-127.56/( ( 10.92 + 11.326 )/ 2 )
=-127.56/11.123
=-1,146.81 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.048 + 0.229 + 3.968) - (30.109 + 0 + 1.181)
=-27.045

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.329 + 0.174 + 5.154) - (16.349 + 0 + 1.297)
=-11.989

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Anteris Technologies Global's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=-141.518/1064.090
=-13.30 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Anteris Technologies Global EBIT Related Terms


Anteris Technologies Global EBIT Historical Data

* Premium members only.

The historical data trend for Anteris Technologies Global's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anteris Technologies Global EBIT Chart

Anteris Technologies Global Annual Data
Trend Jun16 Jun17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -21.68 -43.62 -69.83 -119.88 -141.70

Anteris Technologies Global Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -34.76 -32.32 -33.65 -43.67 -31.89

ASX:AVR vs INMD, QDEL, SSII: EBIT Comparison

For the Medical Devices subindustry, Anteris Technologies Global's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anteris Technologies Global EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Anteris Technologies Global's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Anteris Technologies Global's EV-to-EBIT falls into.


ASX:AVR
50GF Score
Anteris Technologies Global Corp ASX:AVR
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Anteris Technologies Global EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was A$-141.52 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of A$-141.52 Mil mean?
Anteris Technologies Global (ASX:AVR) has a EBIT of A$-141.52 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Anteris Technologies Global.
Is Anteris Technologies Global's EBIT too high?
Anteris Technologies Global's current EBIT is A$-141.52 Mil. Overall, Anteris Technologies Global has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does Anteris Technologies Global's EBIT compare to INMD and QDEL?
Anteris Technologies Global's EBIT of A$-141.52 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Devices & Instruments company?
A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Anteris Technologies Global. Anteris Technologies Global's current EBIT is A$-141.52 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anteris Technologies Global stock overvalued right now?
Anteris Technologies Global (ASX:AVR) has a current EBIT of A$-141.52 Mil. The current EBIT is A$-141.52 Mil. Anteris Technologies Global's overall GF Score™ is 50/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Anteris Technologies Global (ASX:AVR), the current EBIT is A$-141.52 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Anteris Technologies Global Business Description

Other Exchanges AVR:USA
Address 9 Sherwood Road, Level 3, Suite 302, Toowong Tower, Toowong, QLD, AUS, 4066
Anteris Technologies Global Corp is a structural heart company focused on advancing cardiac care through science-driven innovations aimed at restoring heart valve patients to healthy function. Its key product, the DurAVR Transcatheter Heart Valve (THV), was designed in partnership with interventional cardiologists and cardiac surgeons to treat Aortic Stenosis, a potentially life-threatening condition caused by narrowing of the aortic valve. The balloon-expandable DurAVR THV is a biomimetic valve designed to mimic the performance of a healthy human aortic valve and replicate normal aortic blood flow. The company operates in United States, Germany, Australia, Switzerland, and Sweden, with the majority of its revenue generated from the United States.
50GF Score

Get the complete analysis for ASX:AVR

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$15.00
Price